Mersana therapeutics to participate in the guggenheim smid cap biotech conference

Cambridge, mass., jan. 30, 2025 (globe newswire) -- mersana therapeutics, inc. (nasdaq: mrsn), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (adcs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the guggenheim smid cap biotech conference on february 6, 2025 at 1:30 p.m. et. a live webcast of this event will be available on the investors & media section of mersana's website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.
SMID Ratings Summary
SMID Quant Ranking